Polatuzumab Vedotin Combined with Bendamustine and Rituximab for Relapsed/refractory Diffuse Large B-cell Lymphoma: A Systematic Review Protocol

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Aug 1

PMID 39088571

Authors

Mohammadreza Eslami

Mahdi Mehrabi

Mehrdad Payandeh

Fakhredin Saba

Affiliations

Soon will be listed here.

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma subtype with a significant relapse rate and poor prognosis in relapsed/refractory (R/R) patients. Polatuzumab vedotin in combination with bendamustine and rituximab (Pola-BR) has demonstrated promising efficacy and safety as salvage therapy for R/R DLBCL. This systematic review protocol aims to comprehensively evaluate the efficacy of Pola-BR for the treatment of R/R DLBCL by synthesizing data from relevant randomized controlled trials.

Methods: This protocol details the eligibility criteria, search strategy, study selection, data extraction, and analysis methods for the systematic review. Randomized controlled trials comparing Pola-BR with other interventions for R/R DLBCL will be included. The primary endpoint is overall survival, with secondary endpoints being progression-free survival and incidence of adverse events. A comprehensive search will be conducted across databases such as Medline/PubMed, Cochrane Library, Web of Science, Scopus, EMBASE, ProQuest, EU Clinical Trials Register, WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov from the January 2000 to April 2024. To assess the potential risk of bias, the Cochrane Risk of Bias 1 tool will be used. Data synthesis will utilize fixed-effect or random-effects models, and subgroup and meta-regression analyses will examine heterogeneity. Additionally, publication bias and sensitivity analyses will be performed, and the GRADE approach will be applied to assess the certainty of the evidence.

Conclusion: This systematic review and meta-analysis protocol provides a rigorous framework for evaluating the efficacy of Pola-BR in the treatment of R/R DLBCL. The results will inform clinical decision-making and guideline development, addressing the unmet need for effective and tolerable treatments for this challenging patient population. Potential limitations and biases will be acknowledged, and future research directions will be discussed.

References

Minozzi S, Cinquini M, Gianola S, Gonzalez-Lorenzo M, Banzi R . The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application. J Clin Epidemiol. 2020; 126:37-44. DOI: 10.1016/j.jclinepi.2020.06.015. View

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View

Myung S . How to review and assess a systematic review and meta-analysis article: a methodological study (secondary publication). J Educ Eval Health Prof. 2023; 20:24. PMC: 10449599. DOI: 10.3352/jeehp.2023.20.24. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Li Y, Hwang W, Maude S, Teachey D, Frey N, Myers R . Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies. Clin Cancer Res. 2022; 28(18):3940-3949. PMC: 9481718. DOI: 10.1158/1078-0432.CCR-22-0560. View

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

Sehn L, Salles G . Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021; 384(9):842-858. PMC: 8377611. DOI: 10.1056/NEJMra2027612. View

Payandeh Z, Alagheband Bahrami A, Hoseinpoor R, Mortazavi Y, Rajabibazl M, Rahimpour A . The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2018; 109:2415-2426. DOI: 10.1016/j.biopha.2018.11.121. View

Sehn L, Herrera A, Flowers C, Kamdar M, McMillan A, Hertzberg M . Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019; 38(2):155-165. PMC: 7032881. DOI: 10.1200/JCO.19.00172. View

10.

Babic A, Barcot O, Viskovic T, Saric F, Kirkovski A, Barun I . Frequency of use and adequacy of Cochrane risk of bias tool 2 in non-Cochrane systematic reviews published in 2020: Meta-research study. Res Synth Methods. 2024; 15(3):430-440. DOI: 10.1002/jrsm.1695. View

11.

Bishop M, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N . Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2021; 386(7):629-639. DOI: 10.1056/NEJMoa2116596. View

12.

Kim J, Cho J, Yoon S, Kim W, Kim S . Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis. Cancer Res Treat. 2023; 55(3):1031-1047. PMC: 10372592. DOI: 10.4143/crt.2022.1658. View

13.

Molina M, Hoffman E, Stokes J, Kummet N, Smith K, Baker F . Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death. Front Immunol. 2021; 12:699128. PMC: 8264365. DOI: 10.3389/fimmu.2021.699128. View

14.

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

15.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

16.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

17.

Jeon S, Kim T . Application of the revised Cochrane risk of bias tool for acupuncture trials: a preliminary comparative analysis of inter-rater reliability. Acupunct Med. 2022; 40(3):268-269. DOI: 10.1177/09645284221076508. View

18.

Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018; 20(1):31-42. PMC: 6733402. DOI: 10.1016/S1470-2045(18)30864-7. View

19.

Thuresson P, Vander Velde N, Gupta P, Talbot J . A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma. Adv Ther. 2020; 37(12):4877-4893. PMC: 7595978. DOI: 10.1007/s12325-020-01507-7. View

20.

Flowers C, Odejide O . Sequencing therapy in relapsed DLBCL. Hematology Am Soc Hematol Educ Program. 2022; 2022(1):146-154. PMC: 9820056. DOI: 10.1182/hematology.2022000332. View